UroGen Pharma Ltd. (URGN) Institutional Investor Snapshot (190 Funds, Q2 2026)

URGN ranks #3129 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

URGN is a top-conviction position for Acorn Capital Advisors, LLC — at 16.8% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in URGN belongs to Rtw Investments, LP, but the position matters far more to Acorn Capital Advisors, LLC, who has 16.8% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Opaleye Management Inc. has added to its URGN position for two straight quarters, increasing it by $46.7M to reach $53.0M today.

Ken Griffin has trimmed its URGN position for two straight quarters, cutting it by $16.3M while still holding $3.0M.

URGN is up 2.4% today, and institutions have been net buyers of $116.1M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

URGN reported a net loss of $97.6M over the trailing twelve months.

• Not yet profitable — net loss of $97.6M over the trailing twelve months
• Revenue grew 100.3% year over year
• Net income improved year over year, from -$155.0M to -$97.6M
• Operating cash flow was negative, using $162.4M in cash
• Current ratio of 4.01x — enough short-term assets to cover short-term liabilities